A recent industry podcast featuring CEO of Corealis Pharma, David Leroux-Petersen and CCO of Bora Pharmaceuticals, Jean-Baptiste Agnus, explores how stronger collaboration between CDMOs may help reduce complexity and create a more seamless path through development.
Drug development rarely follows a straight line. Sponsors must navigate formulation challenges, analytical requirements, clinical manufacturing needs, packaging considerations, scale-up strategies, and ultimately commercial readiness. Along the way, they often engage multiple partners, each bringing specialized expertise.
While this model offers access to highly specialized capabilities, it can also introduce another challenge: managing transitions.
As programs move from one stage to another, sponsors can find themselves coordinating multiple vendors, repeating onboarding activities, transferring technical knowledge, and maintaining alignment across different teams and systems. These moments are often where complexity begins to accumulate.
The question many organizations are increasingly asking is:
Can better collaboration between development partners simplify the process?
That topic is explored in a recent podcast from Off Script and focuses on how CDMO-to-CDMO collaboration could help reduce friction and improve continuity throughout drug development.
Why Collaboration Matters
Development delays are not always caused by scientific barriers. In many cases, inefficiencies emerge during the movement of information, processes, and decision-making between organizations.
Common challenges can include:
- Repeated technology transfers
- Communication gaps across multiple teams
- Misalignment between early development and later manufacturing requirements
- Reduced visibility as projects move between organizations
- Delays created by disconnected workflows
For emerging and clinical-stage companies operating against funding milestones and development timelines, these challenges can become increasingly important.
Moving Beyond Individual Vendors
The conversation across the industry appears to be shifting from identifying a single outsourcing partner toward building stronger development ecosystems.
Strategic collaboration between organizations can create:
Greater continuity
Project knowledge and decisions move more effectively across stages.
Earlier planning for future requirements
Commercial and manufacturing considerations can be introduced earlier.
Reduced operational friction
Aligned processes and communication structures can help minimize unnecessary delays.
Improved visibility
Sponsors gain a more connected understanding of program progression.
Ultimately, the objective is not simply expanding capabilities. The goal is creating a smoother experience for sponsors and reducing complexity where possible.
What This Means for Drug Developers
As therapies become more complex and timelines become increasingly compressed, collaboration may become an important differentiator in how development programs are executed.
The strongest models may not necessarily be built around individual organizations operating independently, but around connected teams that work together with shared objectives and aligned execution.
This topic and its broader implications are explored in more detail in the podcast discussion below.
Interested in discussing how an integrated development approach could support your program?
Contact Corealis
Corealis’ experts are ready to answer any queries about the company’s oral solid dose offering, including its development and manufacturing capabilities.
